AstraZeneca gets regulator’s nod to market cancer drug Imfinzi for additional indication
The Hindu
AstraZeneca receives approval to market Imfinzi in India for advanced endometrial cancer treatment, enhancing therapeutic options.
AstraZeneca Pharma India Ltd on Tuesday (February 10, 2026) said it has received permission from India's drug regulator to market Durvalumab solution for infusion used in cancer treatment for an additional indication.
The company has received permission from the Central Drugs Standard Control Organisation (CDSCO), Directorate General of Health Services, to import for sale and distribution of Durvalumab solution for infusion of strengths 120 mg/2.4 ml and 500 mg/10 ml (brand name Imfinzi) for an additional indication, AstraZeneca Pharma said in a regulatory filing.
Through this approval, Durvalumab in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with Durvalumab as monotherapy in endometrial cancer which is mismatch repair deficient (dMMR).
The receipt of this permission paves way for the marketing of Durvalumab solution for infusion 120 mg/2.4 mL and 500 mg/10 mL (Imfinzi) in India for the specified additional indication, subject to the receipt of related statutory approvals, it added.
CPI inflation in India reaches 3.2% in February 2026, with economists predicting further increases due to global supply disruptions.
The rupee settles at 92.17 against the dollar, recovering from record lows amid rising crude prices and market volatility.
Progcap's ProgShakti initiative empowers women entrepreneurs by providing over ₹10,000 crore in unsecured credit, enhancing their financial independence.
Atlassian said on Wednesday it would lay off around 10% of its workforce, or 1,600 employees, to push into artificial intelligence and enterprise sales.
The Pentagon has told its senior leaders that use of Anthropic’s AI tools may continue beyond a previously announced six-month phase-out period if deemed critical to national security, according to an internal memo
Rupee declines 31 paise to 92.32 against the U.S. dollar, impacted by FII outflows and rising crude oil prices.
Follow The Hindu LIVE updates to know about the Liquified Petroleum Gas (LPG) shortage in India, crude oil prices due to the Israel-Iran war.
With LPG shortage hitting day-to-day life in India, data suggest while the nation opted for a dramatic surge in LPG use, especially among poor households, driven by imports there was a no plan to boost long-term, strategic LPG reserves in parallel.
Reliance Industries remains silent after Trump's $300 billion refinery announcement, raising doubts about the deal's validity.
Induction stove adoption in low-income Indian households remains low due to limited electrical infrastructure and high costs despite rising demand.
India's coal stock stands at 210 MT, ensuring an 88-day supply to meet rising power demand ahead of summer.
Investment rule tweaks will benefit electronics and rare earth sector in India, says DPIIT Secretary
DPIIT's investment rule changes will enhance India's electronics and rare earth sectors, boosting capital flow and joint ventures.
ED conducts searches at 19 locations in Haryana and Chandigarh linked to ₹590 crore IDFC First Bank fraud investigation.